GFM
SPRY icon

GF Fund Management’s ARS Pharmaceuticals SPRY Stock Holding History

GF Fund Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Sell
2,094
-114
-5% -$981 ﹤0.01% 497
2026
Q1 		$17.7K Buy
2,208
+266
+14% +$2.55K ﹤0.01% 512
2025
Q4 		$22.6K Sell
1,942
-184
-9% -$1.79K ﹤0.01% 491
2025
Q3 		$21.4K Sell
2,126
-362
-15% -$5.2K ﹤0.01% 480
2025
Q2 		$43.4K Hold
2,488
– – ﹤0.01% 431
2025
Q1 		$31.3K Buy
2,488
+447
+22% +$5.38K ﹤0.01% 454
2024
Q4 		$21.5K Buy
+2,041
New +$28.6K ﹤0.01% 464

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

GF Fund Management's SPRY Position: Q2 2026 in Review

GF Fund Management reduced its ARS Pharmaceuticals (SPRY) stake by 5.2% in Q2 2026, selling an estimated $981 and leaving 2,094 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

GF Fund Management first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $43.4K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • GF Fund Management held 2,094 shares of ARS Pharmaceuticals worth $16.8K as of Q2 2026.
  • GF Fund Management sold 114 ARS Pharmaceuticals shares in Q2 2026, an estimated $981.
  • ARS Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #497 holding.
  • GF Fund Management first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's ARS Pharmaceuticals position peaked at $43.4K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.